Casella G, Rieber J, Schiele T M, Stempfle H-U, Siebert U, Leibig M, Theisen K, Buchmeier U, Klauss V
Department of Cardiology, Ospedale Maggiore, Bologna, Italy.
Z Kardiol. 2003 Aug;92(8):627-32. doi: 10.1007/s00392-003-0948-x.
Fractional flow reserve (FFR) is a measure of coronary stenosis severity that is based on pressure measurements obtained at maximal hyperemia. Therefore, achievement of maximal vasodilatation of the coronary microcirculation is a prerequisite for the measurement of FFR. The study was designed to address the hypothesis that intracoronary adenosine yields more complete vasodilatation of the coronary microcirculation when high doses are used, resulting in a more accurate FFR measurement.
Thirty-six patients with 43 moderate lesions underwent determination of FFR during cardiac catheterization. FFR was calculated in all lesions as the ratio of the distal coronary pressure to the aortic pressure at hyperemia. Different incremental doses of intracoronary adenosine (16, 24, 32 and 40 microg for both coronary arteries) were administered in a randomized fashion.
No adverse events occurred with any intracoronary adenosine bolus. At baseline there were no significant differences for mean aortic and distal coronary pressure, heart rate as well as FFR values between the different doses. FFR was not significantly altered from the different incremental adenosine doses. However, in 27 (63%) out of 43 lesions there was a further reduction of FFR up to 0.23 when a dose >16 microg was injected.
This study suggests that doses of adenosine up to 40 microg are safe and can be used to achieve a more pronounced vasodilatation in individual patients compared to the standard doses. This may have therapeutic impact with FFR values near cut-off points in patients undergoing diagnostic coronary angiography as well as in patients in whom FFR is used to assess the outcome of interventions.
血流储备分数(FFR)是一种基于最大充血时获得的压力测量来评估冠状动脉狭窄严重程度的指标。因此,实现冠状动脉微循环的最大血管扩张是测量FFR的前提条件。本研究旨在验证以下假设:使用高剂量冠状动脉内腺苷时,可使冠状动脉微循环更完全地扩张,从而使FFR测量更准确。
36例患者的43处中度病变在心脏导管插入术期间接受了FFR测定。所有病变的FFR均计算为充血时冠状动脉远端压力与主动脉压力之比。以随机方式给予不同递增剂量的冠状动脉内腺苷(两条冠状动脉均为16、24、32和40微克)。
任何冠状动脉内腺苷推注均未发生不良事件。基线时,不同剂量之间的平均主动脉和冠状动脉远端压力、心率以及FFR值均无显著差异。不同递增腺苷剂量并未使FFR发生显著改变。然而,在43处病变中的27处(63%),当注射剂量>16微克时,FFR进一步降低至0.23。
本研究表明,与标准剂量相比,高达40微克的腺苷剂量是安全的,可用于使个体患者实现更显著的血管扩张。这对于诊断性冠状动脉造影患者中FFR值接近临界点的患者以及使用FFR评估干预结果的患者可能具有治疗意义。